AJR ARRS Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graf, O.
Right arrow Articles by Mueller, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graf, O.
Right arrow Articles by Mueller, P. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

American Journal of Roentgenology, Vol 168, 213-217, Copyright © 1997 by American Roentgen Ray Society

ARTICLES

Enhancement of hepatic parenchyma, aorta, and portal vein in helical CT: comparison of iodixanol and iopromide

O Graf, GS Gazelle, S Kreuzer, EF Halpern, P Boehm, G Lechner and PR Mueller
Department of Radiology, Vienna General Hospital, Austria.

OBJECTIVE: The purpose of this study was to determine hepatic, aortic, and portal vein enhancement with a new dimeric, nonionic, isotonic contrast medium (iodixanol) in a routinely performed helical CT protocol and compare enhancement characteristics with those of a monomeric, nonionic, low-osmolality contrast medium (iopromide). SUBJECTS AND METHODS: In 81 patients, we injected 150 ml of iodixanol (320 mg I/ml), iodixanol (300 mg I/ml), or iopromide (300 mg I/ml). Injection rate was 5 ml/sec. A dual-phase helical CT scan was obtained (first helical scan began at 30 sec. second helical scan began at 70 sec), and enhancement characteristics were assessed. Results were analyzed taking into account various intrinsic parameters of patients. RESULTS: During the second imaging phase, iodixanol at 320 mg I/ml and iodixanol at 300 mg I/ml provided significantly higher enhancement of the liver (75 H, 69 H, 62 H), aorta (144 H, 140 H, 122 H), and portal vein (147 H, 147 H, 118 H) than did iopromide at 300 mg I/ml. No significant differences were observed during the first imaging phase. CONCLUSION: The combination of higher vascular and parenchymal enhancement levels after injection of the isotonic agent may represent a different quality of tissue enhancement. Such an enhancement would be characterized more by a higher contribution of the blood pool compartment to absolute enhancement levels than by a contribution of the interstitial compartment. Further studies are needed to determine whether the use of isotonic agents effects lesion conspicuity.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
S. J. Michel, A. M. Fried, S. Sinha, J. Willson, E. Bensadoun, S. Arnold, and J. L. Buck
Comparison of Iodixanol with Iohexol for Delayed Pelvic Venous Opacification: A Preliminary Study of Potential Use for CT Venography
Am. J. Roentgenol., July 1, 2004; 183(1): 123 - 126.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Roentgen Ray Society.